Robert Wasserman

Stock Analyst at Benchmark

(2.16)
# 1265
Out of 5,218 analysts
113
Total ratings
60.00%
Success rate
16.55%
Average return
23 Stocks
Name Action Price Target Current % Upside Ratings Updated
Anebulo Pharmaceutic...
Reiterates: Speculative Buy
8 8
1.45 451.72% 6 Nov 19, 2024
OmniAb
Reiterates: Buy
8 8
3.8 110.53% 7 Nov 14, 2024
Nephros
Reiterates: Speculative Buy
5 5
1.6 212.5% 3 Nov 12, 2024
Ligand Pharmaceutica...
Maintains: Strong Buy
110 135
116.97 15.41% 9 Nov 8, 2024
Emergent BioSolution...
Maintains: Strong Buy
8 12
8.44 42.18% 17 Nov 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 5 Nov 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 7 Nov 4, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
140 140
138.64 0.98% 9 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Speculative Buy
5 3
0.4 650% 5 Aug 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
95 95
75.59 25.68% 5 Aug 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
60 60
47.98 25.05% 7 Aug 8, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Hold
n/a
n/a n/a 3 Aug 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
12 12
2.04 488.24% 6 Jul 11, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
45 45
43.43 3.62% 6 May 29, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
25
26.67 -6.26% 5 May 13, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
4
2.34 70.94% 1 Mar 7, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
4
1.09 266.97% 1 Mar 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
7
n/a n/a 1 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Speculative Buy
75
1.94 3765.98% 2 Apr 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Hold
n/a
n/a n/a 3 Oct 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Speculative Buy
7
n/a n/a 3 Aug 18, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
580
527.13 10.03% 1 Jul 16, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
1386
n/a n/a 1 Aug 28, 2018